FDA grants approval of ponesimod (Ponvory) for relapsing forms of multiple sclerosis in adults

Approval of this oral selective sphingosine-1-phosphate receptor 1 modulator is based on the 2-year, OPTIMUM Phase III trial which demonstrated superior efficacy in significantly reducing annual relapses, with no worsening of disability vs teriflunomide.

Source:

Biospace Inc.